@HARMONY-Talks: We are happy to share our new video interviews with you, starting with Prof dr Lars Bullinger, Charite University Berlin, HARMONY Partner,. Prof Bullinger explains the HARMONY Work Package 2: Definition of Outcomes, including the pilot bench-to-bedside projects in blood cancers: Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL)
Watch more interviews we filmed at the 23rd Congress of the European Hematology Association, which took place in Stockholm, Sweden from 14 - 17 June, 2018.
Click here to visit the HARMONY Youtube channel >> and listen to:
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
